This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SanDiego-based ServiceNow , the developer of software-as-a-service for enterprise IT management, is expected to price its IPO Thursday, as the first, technology-focused IPO since the Facebook debacle. The firm, which has set initial pricing range of its IPO at between $15.00 and $17.00 READ MORE>>.
SanDiego-based Avidity Bio , a biopharmaceuticals company working on oligonucleotide-based therapies, priced its IPO last night, saying that it will offer up 14,400,000 shares of its common stock at $18.00 The company priced above its initial estimated offering range of $14.00 READ MORE>>.
SanDiego-based ServiceNow has proven that the market for initial public offerings is still strong this morning, opening up at $23.08 The firm priced its IPO above estimates, at $18.00 The firm had earlier estimated an initial pricing range of $15.00 JMI Equity is based in SanDiego. READ MORE>>.
SanDiego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 and $16.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. READ MORE>>.
Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says.
Grab yours today before prices go up. Can’t make the SanDiego. Early bird tickets are on sale now for only $99. Each half-day Xcelerating Life Sciences forum is dedicated to helping industry leaders develop meaningful partnerships and explore bold new ideas to overcome healthcare’s biggest challenges.
Think USV is only invested around Union Square in NYC? And in many communities that are new to building tech startups I’ve found that a lot of angel money is not very sophisticated at investing in startup companies. Actually, there is tons of wealth in SanDiego but it isn’t organized well to support them.
It wins through better distribution, logistics, inventory management, warehousing, customer support, merchandising, cross-selling and ultimately on price & scale. It’s not just big in Dallas but in SanDiego, Phoenix and Sacramento but also Boston, Chicago, Washington and of course San Francisco. And they have.
SanDiego-based TargeGen , a firm developing small molecule kinase inhibitors for the treatment of myelofibrosis (MF) and polycythemia vera (PV), has been acquired by Sanofi-aventis, in a deal worth as much as $560M, the firm said Wednesday. The firm was advised by Peter J. Solomon Company in the deal.
The feature illustrates how Postmates, one of the earlier entrants to the billion-dollar food delivery wars , is trying to remain competitive by appealing to price-sensitive customers. Los Angeles, Miami, New York City, Phoenix, San Francisco, SanDiego, Seattle, Orange County, Calif. and Philadelphia. billion valuation.
SanDiego-based ServiceNow is looking to sell $300M in a secondary IPO offering, according to a filing made by the company Wednesday. ServiceNow went public in June, pricing at $18.00 The firm said it will not receive any proceeds from the sale by the selling stockholders. per share; the firm is now trading around $30.65
Prolific SanDiego angel investor Howard Lindzon , who runs StockTwits , has scored a big exit at one of his portfolio companies, LifeLock , after the firm had its IPO this morning. Lindzon said it was an early angel investor in the company, and made his investment in 2006 at "well under a $10M valuation". and $11.50
The Facebook parent-company saw its stock price get bludgeoned after a bad earnings report showcased that Apple’s ad-blocking changes are shaving billions off its books and the company’s crown jewel — the Facebook platform — has stopped growing and actually shrank this quarter. . Image Credits: Facebook.
Get the details on these developments and more in SanDiego life sciences news: —Evofem Biosciences (NASDAQ: EVFM ) struck a deal to raise up to $80 million in a private placement. The company closed the first $30 million, from Nevada-based investment firm PDL BioPharma (NASDAQ: PDLI ), on Wednesday, with the firm paying a 26.4
SanDiego-based Cibus , a developer of gene editing tools being aimed at use in plant breeding, has pulled its IPO paperwork, saying in a filing that it has decided "not to proceed with the initial public offering of its securities at this time." Cibus had set an estimated initial pricing range of $14.00 READ MORE>>.
He did note that in the four markets where the company has gone live since launching its business in January 2019 — SanDiego, Los Angeles, the Inland Empire , and Sacramento — has yielded an annualized revenue run rate of over $400 million in gross merchandise value (the total value of home sales transacted on its platform).
SanDiego-based StockTwits , the real-time messaging service focused on the stock investing community led by Howard Lindzon, is aiming at the investors relation community with a new service. In particular, StockTwits has addressed some of the compliance concerns of public companies.
SanDiego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M Anaptys priced its IPO on Wednesday night at $15.00 AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. READ MORE>>.
The US biotech and life sciences industry has a long and proud history of driving medical innovations that have improved healthcare outcomes across a wide range of diseases and the overall quality of life for people worldwide.
A portfolio company of SanDiego-based biopharmaceuticals venture investor Versant Ventures is getting set for its IPO this week. Aprea Therapeutics said that estimates its IPO will price between $14.00 Aprea's investment bankers on the IPO are J.P. and $16.00 per share, which could raise as much as $92.0M READ MORE>>.
And the broader question of whether VC’s will continue to invest in the Twitter ecosystem. Discussion: Had a long chat about PicClick , a company founded by Ryan Sit in SanDiego. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges. MetaMarkets.
SanDiego-based biotech developer aTyr Pharma is debuting in its IPO this morning, after pricing its IPO at $14.00 aTyr Pharma was venture backed by Fidelity Investments, Domain Associate, Polaris Partners, Alta Partners, Cardinal Partners, Sofinnova Ventures, and others. per share last night.
Orange County-based KGrid , a cleantech startup working on electric car charging stations, said it has received an investment from German utility RWE , via RWE New Ventures LLC. Financial terms of the investment were not announced. KnGrid was founded by Stephen G. Davis and David Hawkins. READ MORE>>.
SanDiego-based Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B funding round. Rowe Price Associates, Inc., Arsani William, M.D.,
SanDiego-based Arena Pharmaceuticals announced this morning that it has launched a new company, Longboard Pharmaceuticals , with $56M in funding. The new funding comes from Farallon Capital, Cormorant Asset Management, HBM Healthcare Investments, Highside Capital Management, and T.
SanDiego-based Obalon Therapeutics , a publicly held developer of medical devices to treat obesity, has raised $10M in a private placement, the company said this week. The company said it 5,494,506 shares of common stock at a price of $1.82 per share in the offering. Obalon trades on the NASDAQ as OBLN. READ MORE>>.
SanDiego-based Seismic , which develops sales enablement and marketing software, has joined the unicorn club, saying this morning that it has raised $92M in a Series F funding, which values the company at approximately $1.6 Rowe Price, its existing investors. Seismic has now raised a total of $270M in funding.
SanDiego-based Mercato , which provides delivery of items from independently owned grocery and specialty food stores, has launched a new program that offers up unlimited free, same-day grocery delivery from local grocery stores. Mercato is led by founder and CEO Bobby Brannigan. Mercato is led by founder and CEO Bobby Brannigan.
SanDiego-based biopharmaceuticals developer Tracon Pharmaceuticals said in a regulatory filing today that it is estimated its IPO pricing at between $12.00 The companyis venture backed by JAFCO Ventures, New Enterprise Associates, Brookline Investments, Nextech Oncology, BioMed Ventures, along with others. and $14.00
The venture investment, which the SanDiego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region. (In Thompson to its board of directors. In Southern California, rounds that large are more often raised by life sciences companies.)
For this morning's interview, we talked with Noah Auerhahn , President of SanDiego-based Extrabux (www.extrabux.com), an online site focused on providing consumers with comparison shopping combined with discount offers. Noah, thanks for the interview. For people who haven't heard of ExtraBux, what is the site all about?
One of the companies that has taken advantage of that is OneRoof Energy (www.oneroofenergy.com), a SanDiego company headed by David Field. That''s in part because of a significant investment in China around solar manufacturing. Because of that oversupply, the cost of panels and value of solar technology has gone down.
Rustic Canyon is an LA-based, but geography-agnostic VC that is currently investing from a $200 million fund. They were originally founded inside of Times Mirror and had a huge string of major investment success before spinning out as a fully independent fund. The investment will be used for product development initiatives.
SanDiego Tech Coast Angeles. Early Exits describes a strategy for startup investors and entrepreneurs to build a new ventures, prove business models and exit companies in 2-3 years without the need for multi-million dollar investments. Thursday, June 2, 2011 -- Early Exits.
On Wednesday the Cambridge, MA-based company, which was launched last year by Third Rock Ventures, announced that New York investment firm Casdin Capital and SanDiego area-based venture firm Section 32 had co-led its Series B. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
We wanted to be able to invest in our software and our learning tools. Some of the biggest school districts, including LA Unified, SanDiego, and Oakland all use our software. We've been toying with taking an investment for the last three or four years, and were able to meet with the guys at Kennet, and Javier Rojas.
We want to invest in early-stage technology enabled startup businesses – upfront in the funding cycle. In fact, 90% of our investments are either Seed or A-round investments (10% are B-round). We’re a national venture capital investment firm but with our roots firmly in Los Angeles. That’s healthy.
You might look at higher quality / higher price solutions like BMW or Mercedes or you try to see if you can find a bargain with the similar features like a Kia. We do a lot of deals in San Francisco. Either way, it’s natural that buyers “shop around” so expect it as a healthy part of the process.
The New York-based startup said Tuesday that the new funding round, which is being led by Goldman Sachs Private Capital Investing group, brings its total investment to $35 million. Billie, a monthly subscription service for shaving and body care products for women, has raised $25 million.
Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 Cambridge, MA-based Akcea had planned on raising $125 million from the initial public offering, and it hit that target.
Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way.
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Signatories agreed to what they dubbed a New Commitment to Patients, a list of “core principals and actions” promising that “pricing of our medicines at launch will reflect innovation and value to patients” and “any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access.”
The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under the 10 percent limit that CEO Brent Saunders pledged last September, in what he called a “ social contract with patients.” The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content